川芎嗪对冠心病患者血脂质过氧化物等含量的影响

Effect of Ligustrazine on Plasma Lipid Peroxidation,Superoxide Dismutase of the Coronary Heart Disease

本研究将５９例陈旧性心肌梗塞患者随机分为治疗组３１例，对照组２８例。治疗组每天静脉滴注川芎嗪１６０ｍｇ，疗程１０天；测定治疗组川芎嗪静脉滴注前后血脂质过氧化物（ＬＰＯ）、超氧化物歧化酶（ＳＯＤ）、血巯基总量，与对照组比较。结果表明：川芎嗪有降低血ＬＰＯ（Ｐ＜０．０１）、提高血ＳＯＤ活性（Ｐ＜０．０５）、增加血巯基总量（Ｐ＜０．０１）的作用；心绞痛症状和发作明显改善，与对照组比较，差异有显著性意义（Ｐ＜０．０５）。川芎嗪降低血ＬＰＯ含量、提高血ＳＯＤ活性的机理可能与抗血小板聚集及改善心肌缺血、保护心肌细胞膜有关。

A clinical study on 59 remote myocardial infarction cases were divided randomly into treated group(31 cases) and normal control group (28 cases).Treated group used intravenously injected Ligustrazine 160 mg a day for 10 days.The plasma lipid peroxidation(LPO),superoxide dismutase(SOD)and sulfhydryl group were measured before and after treatment in the treated group,in comparing with normal control group.The results showed the levels of LPO significantly reduced(p<0.01),and SOD,sulfhydryl group was obviously increased after Ligustrazine administration(p<0.05).Attack of angina pectoris was reduced.Between these two group,the difference was significant(P<0.05).Mechanism of Ligustrazine in reducing LPO and increasing SOD could be the inhibiting of platelet aggregation,regulating the TXA2/PGI2 ratio in plasma,protecting mycardial cell membrane and improving the mycardial ischemia.Ligustrazine could reduce the production of LPO due to the accelerating clearance of oxygen free radical.